BridgeBio Pharma, Inc.
infigratinib
achondroplasia
Resolved
145days ago
Phase 3 readout · Feb 12, 2026
What's at stake
Phase 3 trial results for infigratinib in achondroplasia are due Feb 12, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“PROPEL 3 successfully met the key secondary endpoint of change from baseline in height Z-score (achondroplasia reference population) at Week 52 (p<0.0001), with an LS mean increase on the treatment arm of +0.41 SD”